Jennifer Marlowe - 13 Feb 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Reporting relationship: CSO
Issuer ticker: SLDB
Reported as of: 13 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Feb 2024, 11:28:35 UTC
Prior SEC filing: 05 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ David Tyronne Howton as attorney-in-fact for Jennifer Marlowe

Key filing fact

Jennifer Marlowe filed Form 4 for Solid Biosciences Inc. (SLDB) on 16 Feb 2024.

Key facts

This page summarizes Jennifer Marlowe's Form 4 filing for Solid Biosciences Inc. (SLDB).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Feb 2024, 11:28.

Change

Previous filing in this sequence was filed on 05 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLDB transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +90,000
Change %
Price: $0.000000
Shares after: 90,000
Date: 13 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $7.85
Footnotes: F1

SLDB transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +45,000
Change %
Price: $0.000000
Shares after: 45,000
Date: 13 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

Footnote F3

The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.